Tesla full self driving software 'suspect,' AMCI Testing says

Investing.com
Updated
Mitrade
coverImg
Source: Shutterstock

Investing.com -- Tesla's (NASDAQ:TSLA) latest version of its Full Self-Driving software is "suspect" and still requires improvement to ensure Robotaxi operations can be safely undertaken, independent automotive research firm AMCI Testing said in a Tuesday statement.   


An extensive 1,000-mile evaluation of Tesla FSD software exposed how often human intervention was required for safe operation, AMCI Testing said. While the Tesla's latest FSD software is "impressive," the automotive research firm said its drivers had to intervene over 75 times during the evaluation; an average of once every 13 miles. 


These result "demonstrates just how far Tesla must go before Robotaxi operations can be safely undertaken," it added just ahead of Tesla's Robotaxi unveiling slated for Oct. 10. 


"Getting close to foolproof, yet falling short, creates an insidious and unsafe operator complacency issue as proven in the test results," said David Stokols, CEO of AMCI Testing's parent company, AMCI Global. 


AMCI Testing said it found that the more miles driven with FSD engaged, the more likely a driver were to encounter these failure modes.


Tesla Inc (NASDAQ:TSLA) was up 1% in recent trading.

* The content presented above, whether from a third party or not, is considered as general advice only.  This article should not be construed as containing investment advice, investment recommendations, an offer of or solicitation for any transactions in financial instruments.

goTop
quote
Do you find this article useful?
Related Articles
placeholder
Lilly, Novo Nordisk Shares Plummet as Trump Announces Price Cut to OzempicOn Thursday, shares of Eli Lilly and Novo Nordisk fell sharply in after-hours trading after President Donald Trump announced a significant price reduction for the diabetes drug Ozempic.
Author  TradingKey
1 hour ago
On Thursday, shares of Eli Lilly and Novo Nordisk fell sharply in after-hours trading after President Donald Trump announced a significant price reduction for the diabetes drug Ozempic.
placeholder
Are European Stocks Peaking? SocGen,Citi Turn Bearish on Q4, U.S. Regional Bank Crisis Adds New RiskA series of bad loan incidents in the U.S. are catalyzing a credit crisis in the banking sector, and these concerns are now spreading to Europe’s top-performing bank stocks this year.
Author  TradingKey
1 hour ago
A series of bad loan incidents in the U.S. are catalyzing a credit crisis in the banking sector, and these concerns are now spreading to Europe’s top-performing bank stocks this year.
placeholder
Nio faces Singapore lawsuit for alleged revenue manipulation as shares plungeNio is being sued by Singapore’s GIC for allegedly inflating over $600 million in revenue through a hidden affiliate.
Author  Cryptopolitan
Yesterday 09: 55
Nio is being sued by Singapore’s GIC for allegedly inflating over $600 million in revenue through a hidden affiliate.
placeholder
TSMC Q3 Net Profit Surges 39% to Record High on Booming AI Demand, HPC Contributes Over Half of RevenueTSMC reported its third-quarter financial results, with net profit soaring 39% year-on-year to a record NT$452.3 billion, significantly beating market expectations of NT$405.47 billion.
Author  TradingKey
Yesterday 09: 44
TSMC reported its third-quarter financial results, with net profit soaring 39% year-on-year to a record NT$452.3 billion, significantly beating market expectations of NT$405.47 billion.
placeholder
Wall Street’s Q3 Earnings Shine, But Red Flags Flash as Non-Bank Lending GrewStrong third-quarter results from major Wall Street banks have kicked off the 2025 earnings season on a high note, with JPMorgan Chase posting record revenue, and Goldman Sachs and Citi delivering their best Q3 ever.
Author  TradingKey
Oct 15, Wed
Strong third-quarter results from major Wall Street banks have kicked off the 2025 earnings season on a high note, with JPMorgan Chase posting record revenue, and Goldman Sachs and Citi delivering their best Q3 ever.